Gilead and Arcus Report Positive Data on Combination Therapy of Domvanalimab and Zimberelimab in Non-Small Cell Lung Cancer, Announce Strategic Reprioritization
ARC-10 Clinical Trial Design and Clinical Significance
Gilead Sciences and Arcus Biosciences have announced results from the ARC-10 (NCT04736173) clinical trial, which evaluated the combination therapy of domvanalimab, an anti-TIGIT monoclonal antibody, and zimberelimab, an anti-PD-1 monoclonal antibody, which the companies are co-developing. The trial was designed to assess the efficacy of the immune checkpoint inhibitor combination as a first-line treatment for patients with advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) with high PD-L1 expression (TPS >= 50%). This study represents an important academic milestone demonstrating how dual blockade of TIGIT and PD-1 can reprogram the tumor microenvironment compared to single PD-1 inhibitor therapy.
Combination Therapy Demonstrates Improved Survival Outcomes
Data from the ARC-10 Part 1 cohort, presented at a medical conference, showed that the combination of domvanalimab and zimberelimab significantly improved survival outcomes compared to zimberelimab monotherapy. The median Progression-Free Survival (mPFS) in the combination arm was 11.5 months, compared to 6.2 months in the monotherapy arm and 9.6 months with platinum-doublet chemotherapy. The combination therapy also reduced the risk of death by 36% (Hazard Ratio, HR = 0.64), and the median Overall Survival (mOS) in the combination arm remained unreached at the time of analysis, demonstrating a strong survival benefit.
Favorable Safety Profile and Low Rate of Adverse Events
A major limitation of combination immunotherapies is toxicity, but domvanalimab has an Fc-silent characteristic, which reduces unnecessary immune cell activation. As a result, the rate of treatment-related adverse events (TRAEs) leading to discontinuation was only 10.5% in the combination arm, significantly lower than the 23.5% observed with platinum-based chemotherapy, demonstrating a superior safety profile. This improved tolerability can significantly contribute to increasing long-term treatment adherence and preserving the quality of life for NSCLC patients.
Strategic Reprioritization and Focus on Later-Stage Trials
Despite the positive efficacy data, Gilead and Arcus have decided to halt further patient enrollment in the ARC-10 trial and to fully revise their pipeline development strategy. This decision is not due to clinical failure but rather a strategic choice to focus clinical resources on STAR-121 (a Phase 3 trial evaluating a 3-drug combination therapy for NSCLC as a first-line treatment) and STAR-221 (a Phase 3 trial evaluating a first-line treatment for gastric cancer), which aim for even greater efficacy. Industry analysts view this as a smart portfolio management strategy to accelerate the commercialization of the most competitive 3-drug combination pipeline in a resource-constrained environment.
In the global Non-Small Cell Lung Cancer (NSCLC) first-line treatment market, which is worth approximately $30 billion (USD) annually, TIGIT and PD-1 dual blockade therapies are considered promising next-generation standard-of-care (SoC) candidates that can overcome the limitations of existing single-agent immunotherapies. The 36% reduction in the risk of death (OS HR 0.64) and the achievement of a Progression-Free Survival (PFS) of 11.5 months in the Phase 3 ARC-10 trial have attracted significant attention from researchers, as they reconfirm the clinical efficacy in the TIGIT target area, where Roche's tiragolumab and MSD's vibostolimab had previously shown limited efficacy due to issues with efficacy and adverse event control. Gilead and Arcus's decision to halt further enrollment in the ARC-10 trial and to focus their resources on the later-stage STAR-121 and STAR-221 trials, which evaluate 3-drug combination therapies with the addition of chemotherapy, is interpreted as a medium- to long-term market penetration strategy to gain a competitive advantage. From an investor perspective, while the early termination of the trial may raise concerns about a short-term slowdown in momentum, the success of the upcoming STAR series Phase 3 trials will be a key indicator for determining Arcus's corporate value and the overall success of the large-scale co-development partnership between the two companies.
Source: ClinicalTrials.gov (api_ct)